Cover Image

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	R. Sinha, S. L. Gillespie, P. Brinkman, P. Bassett, K. A. Lockman, A. J. Jaap, J. A. Fallowfield, P. C. Hayes, J. N. Plevris
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
by: Takefumi Kimura
Published: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
by: C. Ramos‐Belinchon, et al.
Published: (2025)

Editorial: Cardiometabolic criteria matters inMASLD
by: Margaret L. P. Teng, et al.
Published: (2024)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
by: Wah‐Kheong Chan, et al.
Published: (2024)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
by: Federica Tavaglione, et al.
Published: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
by: Daniel Q. Huang, et al.
Published: (2026)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
by: Maral Amangurbanova, et al.
Published: (2024)

Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
by: Yee Hui Yeo, et al.
Published: (2025)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
by: Nobuharu Tamaki, et al.
Published: (2025)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
by: Muhammad Abubakr, et al.
Published: (2025)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
by: Eduardo Vilar‐Gomez, et al.
Published: (2025)

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH
by: Brent A. Neuschwander‐Tetri, et al.
Published: (2025)

Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study
by: Federico Perna, et al.
Published: (2026)

MELD 3.0 Improves Risk Stratification and Mortality Prediction in Hepatorenal Syndrome‐Acute Kidney Injury: A Multicentre Study
by: Jing Ma, et al.
Published: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
by: Suzanne Sharpton, et al.
Published: (2026)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
by: A. B. Fons, et al.
Published: (2026)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
by: Darren Jun Hao Tan, et al.
Published: (2024)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
by: Xiaojuan Liu, et al.
Published: (2025)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
by: Mark C. C. Cheah, et al.
Published: (2025)

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
by: Daniela S. Allende, et al.
Published: (2024)

Editorial: Tumour Burden Score and Extrahepatic Progression After TACE —Refining Risk Stratification Beyond the Liver
by: Chien‐Wei Su
Published: (2026)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
by: Maryam Zafer, et al.
Published: (2024)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
by: A. B. Fons, et al.
Published: (2026)

Association Between Volume, Intensity and Rhythm of Physical Activity Measured by Accelerometer and Risk of All‐Cause and Cause‐Specific Mortality in Individuals With MASLD
by: Yu Peng, et al.
Published: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
by: Jiru Li, et al.
Published: (2025)

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
by: Hannah Mohr, et al.
Published: (2025)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
by: Yuanyan Sun, et al.
Published: (2026)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
by: Stuart McPherson, et al.
Published: (2024)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
by: Kaleb Tesfai, et al.
Published: (2026)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
by: C. C. Mark Cheah, et al.
Published: (2025)

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study
by: Christy Riggott, et al.
Published: (2025)

Review article: Diagnosis and management of laryngopharyngeal reflux
by: Amanda J. Krause, et al.
Published: (2024)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
by: Vincent L. Chen
Published: (2025)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
by: Hassan Javed, et al.
Published: (2025)

Editorial: Proton Pump Inhibitors and the Changing Face of Spontaneous Bacterial Peritonitis
by: S. Quickert, et al.
Published: (2026)

Letter: Enhancing HCC Surveillance– GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety
by: Ibrahima Gueye
Published: (2025)

Editorial: ICG ‐ R15 by PDD —A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease
by: Yixuan Zhu, et al.
Published: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
by: Mohamed El‐Kassas, et al.
Published: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
by: Mary Yue Wang, et al.
Published: (2025)

Editorial: Enriching our understanding of MASLD through representation of under‐reported populations
by: Niharika Samala, et al.
Published: (2024)